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Plasma potassium response to acute respiratory alkalosis. Acute
respiratory alkalosis (hyperventilation) occurs in clinical settings associ-
ated with electrolyte-induced complications such as cardiac arrhythmias
(such as myocardial infarction, sepsis, hypoxemia, cocaine abuse). To
evaluate the direction, magnitude and mechanisms of plasma potassium
changes, acute respiratory alkalosis was induced by voluntary hyperventi-
lation for 20 (18 and 36 liter/mm) and 35 minutes (18 liter/mm). The
plasma potassium response to acute respiratory alkalosis was compared to
time control, isocapnic and isobicarbonatemic (hypocapnic) hyperventila-
tion as well as beta- and alpha-adrenergic receptor blockade by timolol
and phentolamine. Hypocapnic hypobicarbonatemic hyperventilation(standard acute respiratory alkalosis) at 18 or 36 liter/mm ( PCO2 — 16
and —22.5 mmHg, respectively) resulted in significant increases in plasma
potassium (ca + 0.3 mmollliter) and catecholamine concentrations. Dur-
ing recovery (post-hyperventilation), a ventilation-rate-dependent hy-
pokalemic overshoot was observed. Aipha-adrenoreceptor blockade oblit-
erated, and beta-adrenoreceptor blockade enhanced the hyperkalemic
response. The hyperkalemic response was prevented under isocapnic and
isobicarbonatemic hypocapnic hyperventilation. During these conditions,
plasma catecholamine concentrations did not change. In conclusion, acute
respiratory alkalosis results in a clinically significant increase in plasma
potassium. The hyperkalemic response is mediated by enhanced alpha-
adrenergic activity and counterregulated partly by beta-adrenergic stimu-
lation. The increased catecholamine concentrations are accounted for by
the decrease in plasma bicarbonate.
Acute respiratory alkalosis is the frequent acid-base disorder
that results from hyperventilation. Hyperventilation is a common
and important clinical event which occurs in response to pain
(myocardial infarction), anxiety (stage fright, panic attacks), drugs
(cocaine), hypoxemia (asthma attacks, pulmonary thromboembo-
lism) and infection (sepsis). The importance of recognizing the
electrolyte disturbances (that is, altered potassium homeostasis)
produced by acute respiratory alkalosis has been emphasized
owing to the potential for electrolyte-induced complications such
as cardiac arrhythmias. The clinical importance attributed to
alterations in potassium homeostasis during acute hyperventila-
tion is underscored by the practice of administering potassium
salts to treat hyperventilation-induced electrocardiographic ab-
normalities [1, 2].
Although, according to standard textbooks, it seems widely
accepted that acute respiratory alkalosis results in hypokalemia in
humans [3], a critical review of the literature reveals conflicting
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data regarding the plasma potassium response to acute respira-
tory alkalosis. The available studies in humans report increases [4,
51, no changes [6—11] and decreases [12—18] in the plasma
potassium concentration. The reasons for these discrepancies are
unknown but might involve the confounding influences of anes-
thesia, failure to control baseline potassium values and—in older
studies—methodological problems concerning plasma and serum
potassium determinations. In addition, no previous reports yield
any insight into the mechanism(s) of the changes in plasma
potassium concentration in response to acute respiratory alkalo-
sis.
In view of these apparent discrepancies between current clinical
teaching and experimentally derived conclusions as well as the
clinical importance of such information, we designed the present
studies to re-evaluate the plasma potassium response to acute
respiratory alkalosis in unanesthetized human subjects. Alkalemia
(increase in blood pH) has been implicated to cause a transcel-
lular shift of potassium from the extra- into the intracellular space,
whereas hypobicarbonatemia that also occurs in acute respiratory
alkalosis has been shown to raise plasma potassium concentration
independent of changes in blood pH [19, 201. Accordingly, we also
evaluated the possibility that bicarbonate-induced changes in
plasma potassium concentration might modulate the magnitude
or even determine the direction of the plasma potassium response
in acute respiratory alkalosis.
The acute transcellular distribution of potassium ions is regu-
lated by many hormones [21] by virtue of their effect on the
Na/K-ATPase and/or sodium and potassium membrane perme-
abilities. Alpha-adrenergic agonists [21—23] inhibit transfer of
potassium into cells (impair extrarenal potassium disposal), while
insulin and beta-2-adrenergic agonists [22, 24] stimulate cellular
uptake of potassium (improve extrarenal potassium disposal).
Accordingly, we analyzed the hormonal responses to acute respi-
ratory alkalosis and evaluated the influence of alterations in
adrenergic tone by performing the hyperventilation experiments
in the presence and absence of beta- or alpha-adrenergic receptor
blockade.
Methods
The protocol was designed to measure the systemic electrolyte,
endocrine and acid-base responses to acute voluntary hyperven-
tilation (acute respiratory alkalosis) in normal subjects. In each
protocol at least 6 of 10 normal, male subjects [mean age (±sD)
27.4 3.0 years; weight, 72.6 6.1 kg] were studied. None were
smokers nor were taking any drugs or medicatiOn before or during
the study. In each protocol, they abstained from foods containing
217
218 Krapf et at: K response to acute respiratoiy alkalosis
caffeine for 12 hours. Data collection was initiated at noon, four
hours after a light breakfast. The time of the experiments was
identical for all protocols.
Heparinized blood samples for plasma electrolyte, plasma
hormone and blood acid-base analysis were obtained from a
cannulated forearm vein without venous stasis. EDTA-collected
plasma was obtained for atrial natriuretic peptide assay.
All subjects volunteered for the study and gave informed
consent. The study protocol was approved by the ethics committee
of the University of Berne School of Medicine.
Experimental design
After placing an intravenous cannula into a forearm vein, the
subjects rested for 30 minutes while recumbent. A second cannula
was placed simultaneously into a vein of the opposite arm when
required by an infusion protocol. Acute respiratory alkalosis was
induced by voluntary hyperventilation for 20 minutes at 18 and 36
liter/mm, respectively. In one protocol, prolonged hyperventila-
tion for 35 minutes (18 liter/mm) was examined. Humidified air or
an air/carbon dioxide mixture was inhaled from a pressurized
reservoir (relative humidity at least 50%, temperature 24°C)
through a mouthpiece (nares occluded). The inspiratory gas
volume was monitored with a flow meter and conducted into the
reservoir, the volume of which was held constant by the subject's
self-directed rate of ventilation. Expiratory gas exited directly to
room air through an expiratory valve in the mouth piece.
Blood samples were drawn —10, —5 and 0 minutes before, +15
and +20 minutes during, and +5, +10, +15, +45 and +105 (some
experiments) minutes after hyperventilation.
The following nine studies (subjects serving as their own
controls) were performed: (1.) control (spontaneous breathing of
room air), N = 10; (2.) hypocapnic hyperventilation by inspiration
of room air at 18 liter/mm, N = 8; (3.) hyocapnic hyperventilation
by inspiration of room air at 36 liter/mm, N = 8, (4. and 5.)
isocapnic hyperventilation (as a control for muscle work) by
inspiration of air/carbon dioxide mixture (95.1% air/4.9% carbon
dioxide) at 18 and 36 liter/mm, N = 6, respectively; (6.) hypocap-
nic hyperventilation by inspiration of room air at 18 liter/mm with
previous beta blockade (10 mg of timolol p.o., a non-selective
beta-antagonist, 4 hours before the study, N = 8); (7.) hypocapnic
hyperventilation by inspiration of room air at 18 liter/mm with
concomitant alpha-blockade (phentolamine administered as a 5
mg intravenous loading dose over three minutes immediately
before hyperventilation, followed by a constant infusion of 0.5
mg/mm for the entire study), N 6; (8.) hypocapnic isobicarbon-
atemic hyperventilation by inspiration of room air at 18 liter/mm
plus simultaneous infusion of sodium bicarbonate (N = 6); (9.)
prolonged hypocapnic hyperventilation for 35 minutes at 18
liter/mm, N = 5. The amount of sodium bicarbonate needed to
maintain isobicarbonatemia was calculated from the fall in plasma
bicarbonate concentration during the previous hypocapnic, hypo-
bicarbonatemic hyperventilation assuming a volume of distribu-
tion for bicarbonate of 50% of body weight. One third of the total
dose was infused during the first five minutes of hyperventilation
with the remainder infused during the last 15 minutes of hyper-
ventilation.
Analytical procedures
All measurements were performed in duplicate. The pH and
PCO2 were determined in blood anaerobically at 37°C (Corning
model 278 blood gas analyzer) and plasma bicarbonate calculated
using a pK' of 6.10 and a solubility coefficient of 0.0301. Plasma
electrolytes and creatinine were determined as previously de-
scribed [25].
Plasma norepinephrine and epinephrine levels were estimated
by use of high-performance liquid chromatography [26]. Radio-
immunoassay methods were used for the determinations of
plasma renin activity [27], aldosterone [28], glucagon [29], insulin
[30], ANP [31] and vasopressin [32].
All values are expressed as means standard error of the
mean. Statistical evaluations were made by analysis of variance for
repeated measures. A P value of less than 0.05 was accepted to
indicate statistical significance.
Results
Hypocapnic hyperventilation
Moderate, voluntary hypocapnic hyperventilation at 18 liters
per minute resulted in a decrease in PCO2 by 15.8 1.7 mm Hg
and a significant, reversible increase in the plasma potassium
concentration by 0.31 0.06 mmol/liter (P < 0.001 vs. control;
Table 1, Fig 1). More profound hyperventilation at 36 liters per
minute (Table 1) resulted in a greater degree of hypocapnia
(decrease in PCO2 by 22.5 1.5 mm Hg, P < 0.005 vs.
hyperventilation at 18 liters per minute), but did not enhance the
hyperventilation-induced rise in plasma potassium concentration
(+ 0.30 0.07 vs. 0.31 0.06 mmol/liter; Fig. 1). Upon cessation
of hyperventilation, plasma potassium concentration fell precipi-
tously within five minutes by 0.40 0.05 mmol/iiter in the 18 liter
and by 0.81 0.08 mmol/liter in 36 liter hyperventilation protocol
(P < 0.005 vs. 18 liter protocol). Only in the 36 liter protocol did
the post-hyperventilation fall in potassium attain levels that were
significantly lower than control: at 10 minutes post-hyperventila-
tion (36 liters) the plasma potassium concentration was 0.55 0.6
mmol/liter below control (P < 0.001; Fig. 1). In both protocols,
both PCO2 and plasma potassium concentration returned to
control levels after 65 (18 liter protocol) and 105 minutes (36 liter
protocol), respectively. Pre-hyperventilation control values for
plasma potassium in each group were stable as evidenced by the
slopes of the individual subject's [K]p versus time: —0.01 0.01
mmol/liter per minute (NS), control group, —0.01 0.02 mmoi/
liter per minute (NS), hypocapnic hyperventilation (18 liters), and
0.01 0.01 mmol/liter per minute (NS), hypocapnic hyperventi-
lation (36 liters). Stability of baseline potassium concentration is
further illustrated by the nearly identical plasma potassium values
in the time control study over the whole observation period (Table
1, Fig 1).
The endocrine response to hyperventilation is shown in Table 2.
While hypocapnic hyperventilation (18 liters) resulted in signifi-
cant increases in both epinephrine (+290 11 pg/mi, P < 0.001)
and norepinephrine plasma concentrations (+326 37 pg/ml,
P < 0.001), insulin, glucagon, renin acitvity, aldosterone, vaso-
pressin and atrial natriuretic peptide plasma concentrations did
not change significantly. Hypocapnic hyperventilation at 36 liters
per minute increased plasma epinephrine by + 315 17 pg/mi
and norepinephrine concentrations by +354 41 pg/mi. Both
increases were not significantly different from the rise in response
to hypocapnic hyperventilation at 18 liter/mm. All other hor-
mones did also not change significantly during the 36 liter
protocol (data not shown).
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Table 1. Effect of acute hyperventilation on vital signs, acid-base parameters, plasma potassium and plasma phosphate concentrations in normal
subjects
Protocol Period
MAP
mm Hg Pulse rate pH
PCO2
mm Hg
HC03 K P04
mmol/liter
Control 0
+20 mm
+65 mm
93 491 390 3
64 360 461 3
7.41 0.01
7.41 0.01
7.42 0.01
42.8 1.7
42.1 1.8
42.7 1.5
26.2 0.8
25.8 0.7
26.8 0.7
3.69 0.08
3.74 0.07
3.79 0.09
1.09 0.05
1.10 0.06
1.11 0.05
Hypocapnic hyperventilation
18 liter/mm
C
HV
R
90 3101 589 4
61 3112 566 5
7.40 0.01
7.55 0.02
7.40 0.02
43.1 1.8
27.3 1.7
42.0 4.1
25.8 0.8
23.1 0.7k'
25.2 0.7
3.63 0.11
3.93 0.07a
3.71 0.07
1.12 0.06
0.89 o.o6
1.07 0.07
Isocapnic hyperventilation C 89 4 60 4 7.42 0.01 42.6 1.4 26.7 0.9 3.72 0.07 1.05 0.06
18 liter/mm HV
R
91 688 5 71 661 5 7.42 0.017.42 0.01 44.0 1.941.9 1.4 27.6 0.826.3 0.6 3.86 0.093.92 0.10 1.05 0.061.11 0.06
Hypocapnic hyperventilation C 88 4 64 4 7.40 0.02 42.8 1.8 25.6 0.8 3.76 0.04 1.14 0.07
36 liter/mm HV
R
102 589 5 116 760 6 7.65 0.03a7.39 0.02 20.3 3.2a41.5 2.1 21.6 1.la24.3 0.9 4.07 0.08a3.81 0.09 0.64 0.091.01 0.08
During Control, subjects were breathing spontaneously, blood samples were drawn at the times indicated and correspond to the periods C (control),
HV (hyperventilation) and R (recoveiy) during hyperventilation experiments. Plus-minus values are mean SE. MAP denotes mean arterial pressure,
PCO2 carbon dioxide tension, HC03 bicarbonate, K potassium and P04 phosphate. To convert values for PCO2 to kilopascals, multiple by 0.1333.
a P < 0.001 for the comparison to control period
b P < 0.005 for the comparison to control period
The changes in plasma catecholamine concentrations in re-
sponse to hypocapnic hyperventilation are reflected by the
changes in vital signs (Table 1): mean arterial blood pressure
(+11 4 mm mHg) and pulse rate (+51 7) both increased
significantly (P < 0.001 compared to control) in response to
hypocapnic hyperventilation. Hypocapnic hyperventilation at 36
liters did not further affect these signs compared to the 18 liter
protocol.
Plasma phosphate concentration fell reversibly by 0.23 0.08
mmol/liter (P < 0.001 compared to control) during 18 liter and by
0.58 0.11 mmol/liter (P < 0.001 compared to both control and
18 liter protocol) during 36 liter hypocapnic hyperventilation
(Table 1).
Isocapnic hyperventilation
In order to differentiate between hypocapnia- and hyperventi-
lation-induced effects a protocol was performed to evaluate the
potassium and endocrine response to isocapnic hyperventilation
(hyperventilation at 18 liter/mm with a 4.9% C02195.1% air
mixture, N = 6). As shown in Tables 1 and 2 and illustrated by
Figure 2, isocapnic hyperventilation at 18 liter/mm did not result
in significant changes in plasma potassium (and phosphate)
concentrations, plasma catecholamine levels, nor in any changes
in mean arterial blood pressure and pulse rate.
In addition, subjects (N = 6) were studied during 36 liter/mm
isocapnic hyperventilation. Again, there were no significant
changes in the electrolyte, endocrine and vital signs response to 36
liter isocapnic hyperventilation. There was a non-significant ten-
dency for this more severe hyperventilation to increase plasma
potassium (+0.13 0.08; P = 0.085).
Isobicarbonatemic hyperventilation
Hypobicarbonatemia has been demonstrated to raise plasma
potassium concentration independent of changes in blood pH [19,
20]. Since acute hypocapnic hyperventilation results in hypobicar-
bonatemia (Table 1), we evaluated the role of hypobicarbon-
atemia in hyperventilation-induced hyperkalemia by performing a
protocol designed to induce isobicarbonatemic hypocapnic hyper-
ventilation (N = 6; see Methods). Figure 2 illustrates that during
isobicarbonatemic hypocapnic hyperventilation at 18 liter/mm
plasma HCO3-concentration did not change significantly while
PCO2 fell to a similar degree as in the hypobicarbonatemic
Hyper-
ventilation
0.4 E *
0.2
E
-0.2
—0.4
—0.6
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Fig. 1. Effect of graded degrees of hyperventilation [18 (•) and 36 (0)
liter/mm, respectively] compared to control (A), spontaneous breathing of
room air) on plasma potassium concentration and blood PCO p < 0.001,
**p < 0.005, and tP < 0.05 for comparisons to control. II P < 0.005 for
the comparison between 36 and 18 liter/mm hyperventilation.
*
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Table 2. Effect of acute hyperventilation on plasma hormone levels in normal subjects
Protocol Period
Epinephrine Norepinephrine .Insulin
jU/mi Glucagonpg/mi
.Renin
ng/mi/hr
Aldosteron
ng/di
Vasopressin
pg/mi
ANP
pg/mi
Control 0
+20 mm
+65 mm
64 9
71 8
70 8
280 32
291 39
295 30
12.5 1.5
11.9 1.1
12.2 1.2
61 364 361 4
2.8 0.3
2.9 0.3
2.9 0.4
5.2 0.6
5.0 0.5
5.1 0.5
2.9 0.3
3.0 0.4
3.2 0.5
34 638 731 6
Hypocapnic hyperventilation C 68 9 295 24 13.5 1.8 58 5 3.0 0.4 5.4 0.4 3.1 0.4 39 5
18 liter/mm HV
R
358 12
78 7 621 31284 27 13.0 1.412.8 1.2 60 361 4 2.9 0.32.9 0.4 5.2 0.55.1 0.4
3.4 0.5
3.7 0.4
41 4
44 7
Isocapnic hyperventilation C 69 7 279 26 12.8 1.0 65 5 2.9 0.4 5.6 0.5 3.2 0.6 32 4
18 liter/mm HV
R
64 9
70 8 298 32281 30 13.0 1.212.5 1.4 67 362 4 2.8 0.32.8 0.4 5.7 0.65.5 0.4 3.4 0.53.6 0.6 38 639 5
During Control, subjects were breathing spontaneously, blood samples were drawn at the times indicated and correspond to the periods C
(Control), HV (hyperventilation), and R (recovery) during the hyperventilation experiments. Plus-minus values are mean SE.
a P < 0.01 for the comparison of control period
hypocapnic hyperventilation experiments (—14.7 1.4 vs. —15.8
1.7 mm Hg; NS). The hyperventilation-induced rise in plasma
potassium concentration was prevented by isobicarbonatemia:
Plasma potassium fell non-significantly by 0.06 0.03 mmol/liter.
Post-hyperventilation plasma potassium fell by 0.44 0.05 mmol/
liter compared to control conditions during isobicarbonatemia
(P < 0.001). This fall was significantly different from the decre-
ment of 0.10 mmol/liter following hypobicarbonatemic hypocap-
nic hyperventilation (P < 0.005). As expected, post-hyperventila-
tion values for bicarbonate (27.0 0.4 mmol/liter) and pH (7.45
0.05) were both significantly greater than in the hypobicarbon-
atemic (18 liter/mm) group, P < 0.025).
Interestingly, isobicarbonatemia also effectively prevented the
hyperventilation-induced rise in plasma catecholamine levels (Fig.
2), indicating that the increased plasma catecholamine concentra-
tion in acute respiratory alkalosis is mediated by the fall in plasma
bicarbonate concentration rather than the fall in PCO2 (hypo-
capnia).
Hypocapnic hyperventilation during alpha- and beta-adrenergic
receptor blockade
Transcellular potassium equilibrium has been shown to be mod-
ulated importantly by alpha- and beta-2-adrenergic stimulation
[22—241. Hyperventilation-induced increases in plasma potassium
concentration were only observed during hypocapnic, hypobicar-
bonatemic hyperventilation (such as in clinical hyperventilation
with acute respiratory alkalosis; Table 1, Figs. 1 and 2). Interest-
ingly, plasma catecholamine levels also increased only during
these conditions (Table 2, Fig. 2). In addition, a strong positive
correlation was obtained for the relationship of increase in plasma
potassium concentration and increase in plasma norepinephrine
levels (Fig. 3). We therefore evaluated the hypotheses that this
catecholamine response might (a) be responsible for the hyper-
ventilation-induced hyperkalemia and (b) modulate the post-
hyperventilation-induced fall in plasma potassium concentration
(post-hyperventilation hypokalemia). To this end, hypocapnic
hypobicarbonatemic hyperventilation was performed during beta-
adrenergic- (timolol p.o., N = 8) and alpha-adrenergic-receptor
blockade (phentolamine intravenously, N = 6).
Figure 4 illustrates that the hyperventilation-induced rise in
plasma potassium concentration was prevented by alpha-adrener-
gic and enhanced by beta-adrenergic receptor blockade. During
hyperventilation plasma potassium concentration increased by
0.06 0.09 mmol/liter (NS vs. time control) in the presence of
phentolamine, but by 0.37 0.06 in the presence of timolol (P <
0.001 vs. time control and < 0.05 vs. hyperventilation in the
absence of timolol). In addition, the post-hyperventilation fall in
potassium concentration was enhanced by alpha-adrenergic, but
attenuated and delayed by beta-adrenergic receptor blockade.
Ten minutes post-hyperventilation, plasma potassium concentra-
tions in relation to control values were as follows: —0.10 0.06
mmol/liter without adrenergic receptor blockade, + 0.08 0.02
mmol/liter in the presence of timolol (P < 0.05) and —0.38 0.12
mmol/liter (P < 0.025) in subjects receiving phentolamine.
The hypokalemia that developed post-hyperventilation could
be due to a combination of a specific post-hypocapnia beta-
adrenergic effect (which follows a specific hypocapnia-induced
increase in alpha adrenergic tone) and the effects of hypocapnia
per Se. Alternatively, it is possible that the plasma potassium
response to acute respiratory alkalosis could be biphasic (increase
and then decrease) with the hyperkalemia induced by a non-
specific brief simultaneous burst of alpha- and beta-adrenergic
activities and/or rapid down-regulation of alpha-adrenoreceptors.
A biphasic effect on the plasma potassium concentration with a
very short-lived initial hyperkalemia (less than 10 mm) has been
observed after epinephrine infusion in a variety of species [33—361.
To differentiate between these two possibilities the effects of
prolonged hyperventilation for 35 minutes at 18 liter/mm on
plasma potassium and catecholamine levels were examined. In
addition, we wished to evaluate the plasma potassium response
during a more clinically relevant time period for acute respiratory
alkalosis. Figure 5 illustrates that stable hyperkalemia persisted
throughout the 35-minute hyperventilation period. Similar to the
20 minute protocol (Fig. 2), significant reversible elevations in
plasma epinephrine and norepinephrine concentrations occurred
as plasma bicarbonate concentration decreased reversibly.
Discussion
The results of the present studies define the alterations in
plasma potassium concentration associated with the commonly
encountered, clinically important acid-base disorder, acute respi-
ratory alkalosis, and clarify the mechanism of hyperventilation-
induced plasma potassium changes. The most important new
findings in this study are: (a) acute respiratory alkalosis (hyper-
ventilation) results in significant hyperkalemia of a magnitude of
likely clinical importance and a rapid, quantitatively impressive
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Fig. 2. Effects of hypocapnic (•), isocapnic (A) and isobicarbonatemic (0)
hyperventilation on plasma potassium concentration, acid-base composition
and plasma catecholamine levels. In each experiments subjects hyperven-
tilated with a minute ventilation rate of 18 liter/mm. *P < 0.001, <
0.005 and fP < 0.05 for the comparisons of isocapnic and isobicarbon-
atemic hyperventilation to hypocapnic hyperventilation, respectively.
fall in the plasma potassium concentration post-hyperventilation
(Table 1, Fig. 1); (b) the increase in plasma potassium concentra-
tion is due to hyperventilation-induced enhancement of alpha-
adrenergic activity (Figs. 2, 3, 4); while (c) the post-hyperventila-
tion fall in plasma potassium concentration is due primarily to
changes in plasma acid-base composition (for example, bicarbon-
ate1) and modulated importantly by alpha- and beta-adrenergic
activity (Fig. 4); and (d) the increased sympathoadrenergic activity
- c a
- o• D
- 0 •
_ool I I I
—100 0 100 200 300 400 500
[Norepinephrine], pg/mi
Fig. 3. Relationship between increases in plasma potassium and plasma
norepinephrine concentrations in response to voluntaty hyperventilation.
Symbols are: () hypocapnic hyperventilation at 36 liter/mm; (LI) hy-
pocapnic hyperventilation at 18 liter/mm; (0) isocapnic hyperventilation
at 36 liter/mm; (•) isocapnic hyperventilation at 18 liter/mm. AfKp =
0.01 ([norepmnephrine]p + 0.07 (r = 0.819).
of acute hyperventilation (acute respiratory alkalosis) appears to
be mediated by a fall in plasma bicarbonate and not by alterations
in PCO2 or pH (Fig. 2).
The present studies provide evidence that when methodological
influences such as anesthesia and muscle work are eliminated or
controlled, the occurrence of acute hypocapnia (acute respiratory
alkalosis) in humans is associated with acute hyperkalemia. The
hyperkalemic response is essentially exclusively attributable to the
consequences of hypocapnia per se, as prevention of hypocapnia
65 during voluntary hyperventilation at 18 or 36 liters per minute
prevented a statistically significant hyperkalemic response. Thus,
the neuromuscular hyperactivity associated with moderate to
severe hyperventilation does not affect plasma potassium concen-
trations significantly.
A critical role for hypocapnia-induced hypobicarbonatemia as
the modulator of hyperkalemia in this acid-base disorder is
defined by the observation that experimental prevention of the
reduction in plasma bicarbonate concentration induced by hy-
pocapnia prevented the occurrence of hyperkalemia. The finding
of significant increases in plasma norepinephrine and epinephrine
concentrations only in hypocapnic subjects permitted to develop
hypobicarbonatemia suggests that hypobicarbonatemia-induced
adrenergic hyperactivity resulted in alpha-adrenergic mediation of
hyperkalemia in acute hypocapnia. This hypothesis is confirmed
by the observation that pretreatment with the alpha-adrenergic
receptor blocker, phentolamine, obliterated the hyperkalemic
response to acute hypocapnia. A catecholamine-independent and
direct role of hypobicarbonatemia in the hyperkalemic response
to acute respiratory alkalosis was not discernible in these studies.
1 The dramatic effect on plasma potassium of a small experimentally
induced primaly increase in plasma HC03 concentration on post-
hyperventilation hypokalemia is illustrated in Fig. 2. This "acid-base"
effect occurred in the absence of altered catecholamine levels, implicating
an etiologic role for plasma HC03 concentration or pH 120].
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Fig. 4. Effect of alpha- and beta-adreneigic receptor blockade on the plasma
potassium and blood PCO2 response to voluntaty hypocapnic hyperventila-
tiOn (18 liter/mm). Symbols are: (A) beta-adrenergic blockade (timolol);
(0) alpha-adrenergic blockade (phentolamine); (•) hyperventilation with-
out inhibitors. tP < 0.05, P < 0.005, P < 0.001 for the comparison of
the changes in the presence and absence of timolol and phentolamine,
respectively.
The present results contrast with the currently accepted view
that acute hypocapnia results in hypokalemia [3]. While it can be
argued that general anesthesia could prevent aipha-adrenergic
agonist effects [37, 38] in studies where anesthetic agents were
employed [12—15, 39—41], additional factors are required to explain
the difference to studies in which acute respiratory alkalosis is
cited to result in hypokalemia in non-anesthetized humans [42—
44]. In the most frequently cited study by Burnell et al [13], the
single patient reported did achieve alkalemia (pH increased from
7.50 to 7.58), but a calculation of the PaCO2 values reveals no
change (PaCO2 decreased from 21.6 to 21.4 mm Hg), indicating
that the alkalemia was induced by hypobicarbonatemia (chiefly
metabolic alkalosis). In other reported human studies, there was
great variability in plasma potassium concentration prior to
hyperventilation and a failure to show recovery [18]. In addition,
three studies showed no change in plasma potassium concentra-
tion during either voluntary or passive hyperventilation [6, 10, 11],
while three frequently cited studies show both increases and
0
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15 20 25 30 3540 45 50 65 105
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Fig. 5. Effect of more prolonged hyperventilation (35 mm at 18 liter/mm) on
the plasma potassium concentration, blood PCO2, plasma bicarbonate and
catecholamine concentrations. 1P < 0.005, P < 0.001 for the comparison
to control.
decreases in plasma potassium concentration during voluntary
hyperventilation [7, 9, 16]. In two rarely cited reports of voluntary
hyperventilation in normal subjects, Yu et al [4] and Hickam et al
[5] demonstrated a mean transitory increase in the serum potas-
sium concentration during acute hypocapnia. Thus, a critical
analysis of previous reports does not support the conclusion that
hypokalemia is a predictable consequence of acute respiratory
alkalosis.
While it is well known that acute respiratory acidosis (hyper-
capnia) increases plasma norepinephrine and epinephrine con-
centrations [45, 46], the present studies provide the only reported
data for normal human subjects for plasma catecholamines in
response to hypocapnia and indicate that both norepinephrine
and epinephrine levels increase significantly. The present results
agree with the observation in splenectomized men that voluntary
hyperventilation increased catecholamine plasma levels [47]. Dur-
ing combined bicarbonate infusion and voluntary hyperventila-
tion, plasma bicarbonate concentrations did not change signifi-
cantly and PCO2 levels fell to the same degree as in control
experiments (isobicarbonatemic hypocapnia), but the rise in
plasma catecholamine levels was prevented (Fig. 2). Thus, our
findings indicate that the increased sympathoadrenergic acitivity
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(increase in plasma catecholamine concentrations) in response to
acute respiratory alkalosis (hyperventilation) is mediated by the
fall in plasma bicarbonate concentration (hypobicarbonatemia)
which is a predictable consequence of acute hyperventilation
(hypocapnia) due to titration of non-bicarbonate buffers. It is
important to point out that our results are consistent with the
finding of increased plasma catecholamine concentrations in
animals in response to an isocapnic fall in plasma bicarbonate by
HCL infusion [48, 49] and the reported increased catecholamine
output from isolated canine adrenal glands in response to exper-
imental isocapnic reduction in the perfusate bicarbonate concen-
tration [50]. Thus, our studies provide evidence that hypobicar-
bonatemia can account for the observed increases in plasma
catecholamine concentrations in acute respiratory alkalosis. The
cellular mechanisms involved remain to be investigated.
The hyperkalemic response to acute respiratory alkalosis is
mainly the consequence of increased alpha-receptor stimulation
as supported by the strong correlation between increases in
plasma norepinephrine and plasma potassium concentrations
(Fig. 3) as well as by the observation that pretreatment with the
aipha-adrenoreceptor blocker, phentolamine, obliterated the hy-
perkalemic response to acute hypocapnia (Fig. 4). However, a
counterbalancing role for a beta-receptor-mediated tendency to
decrease the plasma potassium concentration during acute respi-
ratory alkalosis is supported by the significant exacerbation of
hypocapnia-induced hyperkalemia demonstrated in beta-blocked
(timolol-treated) subjects relative to untreated controls. The
effect of beta-blockade is also demonstrated in the post-hyperven-
tilation period inasmuch as the post-hyperventilation hypokalemic
overshoot is prevented and normokalemia is restored more
rapidly. In contrast, alpha-receptor blockade significantly aggra-
vated the post-hyperventilation hypokalemia (Fig. 4) presumably
by providing an unopposed beta agonist effect.
The cellular mechanisms of adrenoreceptor-mediated extrare-
nal potassium flux remain poorly understood. However, animal
data suggest that alpha-agonist mediated hyperkalemia is modu-
lated, at least in part, by alpha-i and alpha-2 receptor-mediated
activation of hepatic calcium-dependent potassium channels [33—
36]. Beta-agonist mediated hypokalemia is modulated, at least in
part, by beta-i and beta-2 receptor-mediated stimulation of
skeletal muscle Na/K-ATPase [35].
The findings during isocapnic and hypocapnic as well as isobi-
carbonatemic hypocapnic hyperventilation indicate that the rapid,
reversible hypokalemic response observed during the post-hyper-
ventilation period is the consequence of acid-base-induced trans-
cellular potassium transport.1 The development and magnitude of
posthyperventilation hypokalemia is, however, modulated by the
adrenergic nervous system.
Clinical significance
What is the clinical significance of these results? First, diagnos-
tically, hypokalemia can no longer be considered to be a conse-
quence of the common clinical condition, acute respiratory alka-
losis. Hypokalemia in a patient with acute respiratory alkalosis
thus mandates a thorough search for other etiologies (such as
chronic respiratory alkalosis with renal potassium wasting [25] or
a primary disorder of potassium homeostasis). It is also important
that clinicians be aware of the fact that hypokalemia and potas-
sium depletion in this situation may be underestimated in severity
due to a hyperventilation-induced rise in plasma potassium con-
centration. Second, the highly significant and reproducible hy-
perkalemia induced by moderate to severe acute respiratory
alkalosis indicates that the degree of hyperkalemia is of sufficient
magnitude to be of substantial clinical importance, at least when
extrapolated to patients with cardiac disease, diabetes mellitus
(insulinopenia), with pre-existing hyperkalemia or under pretreat-
ment with drugs that affect transcellular potassium balance such
as beta-adrenergic blocker or digitalis. Since these conditions as
well as acute respiratory alkalosis are all very frequent clinical
entities, the potential exists for serious aggravation of these
influences on intracellular and plasma potassium concentrations.
Future studies will be able to test directly the morbidity rate of
hyperkalemia induced in clinical settings such as deliberate hy-
perventilation to control cerebral blood flow. Third, the rapid
changes in cellular and plasma potassium concentrations occur-
ring when acute respiratory alkalosis subsides are predicted to be
associated with rapid changes in membrane potential and thus
create an arrhythmogenic potential. Thus, sudden therapeutic
removal of the cause of acute respiratory alkalosis (for example,
oxygen administration in hypoxia, pain relief in acute myocardial
infarction) could be accompanied by hypokalemia-induced ar-
rhythmias.
In conclusion, acute respiratory alkalosis (hyperventilation)
results in a clinically significant increase in the plasma potassium
concentration in humans. Hyperkalemia is induced by a hypobi-
carbonatemia-mediated increment in alpha-adrenergic activity
and modulated in magnitude by counterbalancing enhanced beta-
adrenergic activity. Abrupt cessation of acute respiratory alkalosis
results in a rapid fall in plasma potassium with a hypokalemic
overshoot.
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